With the recent development of sodium glucose cotransporter-2 inhibitors (SGLT-2i), glucagon-like peptide-1 receptor agonists (GLP1-RA), and nonsteroidal mineralocorticoid receptor antagonists (MRA), there has been a surge of high-quality randomized controlled trials demonstrating substantial benefits of these agents for persons with kidney disease, after a period of relative stagnation.1 The gene discussed is GLP1R; the disease is kidney disorder.